LOS ANGELES, CA / ACCESSWIRE / November 22, 2016 / Second Sight Medical Products, Inc. (EYES) ("Second Sight" or "the Company"), a developer, manufacturer, and marketer of implantable visual prosthetics to provide a form of useful vision to blind patients, announced today that it will be presenting at the 9th annual LD Micro Main Event on Wednesday, December 7, 2016 at 2:30 PM PST (5:30 PM EST) in Track 1.

The Company's CEO, Will McGuire, will be presenting and holding one-on-one meetings with investors throughout the day. A live webcast of the presentation will be available at http://wsw.com/webcast/ldmicro11/eyes.

The LD Micro Main Event is the largest independent conference for small/micro-cap companies and will feature 240 presenting names.

View the Second Sight profile here: http://www.ldmicro.com/profile/EYES

News Compliments of Accesswire.

About Second Sight

Second Sight's mission is to develop, manufacture, and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. Second Sight has developed and now manufactures and markets the Argus® II Retinal Prosthesis System. Enrollment has been completed in a feasibility trial to test the safety and utility of the Argus II in individuals with Dry Age-Related Macular Degeneration. Second Sight is also developing the Orion™ I Visual Cortical Prosthesis to restore some vision to individuals who are blind due to causes other than preventable or treatable conditions. U.S. Headquarters are in Sylmar, California, and European Headquarters are in Lausanne, Switzerland. For more information, visit www.secondsight.com.

About the Argus® II Retinal Prosthesis System

Second Sight's Argus II System provides electrical stimulation that bypasses the defunct retinal cells and stimulates remaining viable cells inducing visual perception in individuals with severe to profound outer retinal degeneration such as retinitis pigmentosa (RP). The Argus II works by converting images captured by a miniature video camera mounted on the patient's glasses into a series of small electrical pulses, which are transmitted wirelessly to an array of electrodes implanted on the surface of the retina. These pulses are intended to stimulate the retina's remaining cells, resulting in the perception of patterns of light in the brain. The patient then learns to interpret these visual patterns, thereby regaining some useful vision. The system is controlled by software and is upgradeable, which may provide improved performance as new algorithms are developed and tested. Therefore current and future Argus II users may benefit from the continuously improving technology. The Argus II is the first artificial retina to receive widespread approval, and is offered at approved centers in Austria, Canada, France, Germany, Italy, the Netherlands, Saudi Arabia, Spain, Switzerland, Turkey, the United Kingdom, and the United States.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com/events for more information.

Investor Relations:
Institutional Investors
In-Site Communications, Inc.
Lisa Wilson, 212-452-2793
President
lwilson@insitecony.com

or

Individual Investors
MZ North America
Greg Falesnik, 949-385-6449
Senior Vice President
greg.falensik@mzgroup.us

or

Media Relations:
Pascale Communications, LLC
Allison Potter, 412-228-1678
Senior Account Executive
allison@pascalecommunications.com

SOURCE: Second Sight Medical Products, Inc. via LD Micro